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Earlier studies at our laboratory indicated that several hydroxy-
lated polychlorinated biphenyls (OH-PCBs) detected in human blood
could speciﬁcally inhibit thyroxine (T4) transport by competitive
binding to the thyroid hormone transport protein transthyretin
(TTR) in vitro. In the present study we investigated the effects of
prenatal exposure to 5 mg/kg body weight of [
14C]-labeled or unla-
beled 4-OH-2,3,3,4,5-pentachlorobiphenyl (4-OH-CB107), one of
the major metabolites of PCBs detected in human blood, from ges-
tation days (GD) 10 to 16 on thyroid hormone status and metabolism
in pregnant rats and their fetuses at GD 17 and GD 20. 4-OH-CB107
is a metabolite of both 2,3,3,4,4-pentachlorobiphenyl (CB-105) and
2,3,4,4,5-pentachlorobiphenyl (CB-118). We were able to show the
accumulation of 4-OH-CB107 in the fetal compartment. The fetal/
maternal ratios at GD 20 in liver, cerebellum, and plasma were 11.0,
2.6, and 1.2, respectively. The
14C-4-OH-CB107-derived radioactivity
in plasma was bound to TTR in both dams and fetuses. Fetal plasma
TT4 and FT4 levels were signiﬁcantly decreased at GD 17 and GD 20
(89% and 41% respectively at GD 20). Fetal thyroid stimulating
hormone levels were increased by 124% at GD 20. The T4 concen-
trations in fetal forebrain homogenates at GD20 were reduced by
35%, but no effects could be detected on brain T3 concentrations. The
deiodination of T4 to T3 was signiﬁcantly increased in fetal forebrain
homogenates at GD 17, and unaltered at GD 20. In addition, no
alterations were observed in maternal and fetal hepatic T4-UDP-
glucuronosyltransferase activity, type I deiodinase activity, and
EROD activity. In conclusion, exposure of pregnant rats to 4-OH-
CB107 results in the distribution of the compound in the maternal
and fetal compartment, which is probably caused by the binding of
the PCB metabolite to TTR. Consequently, TT4 levels in fetal plasma
and brain samples were reduced. Despite reductions in fetal brain T4
levels, the active hormone (T3) in fetal brains remained unaffected.
Key Words: hydroxylated PCB; T3;T 4; thyroid stimulating hor-
mone; glucuronosyltransferase.
Polychlorinated biphenyls (PCBs) are widespread, persistent
environmental pollutants that have been reported to cause a
variety of toxic effects, including neurotoxicity, developmental
toxicity, reproductive toxicity, and carcinogenesis (reviewed in
Peterson et al., 1993; Safe, 1990, 1994; Schantz, 1996; Seegal,
1996). In recent years it has become evident that exposure to
PCBs can also lead to thyroid hormone disturbances in labo-
ratory animals, wildlife, and even humans as reviewed by
Brouwer et al. (1998). Decreased levels of circulating plasma
thyroxine (T4) following PCB exposure have been shown in
both adult (Barter and Klaassen, 1994; Byrne et al., 1987; Van
den Berg et al., 1988) and developing organisms (Collins and
Capen, 1980; Darnerud et al., 1996; Morse et al., 1993, 1996a;
Ness et al., 1993; Seo et al., 1995). Plasma thyroid hormone
levels can be decreased by xenobiotic compounds by at least 3
known mechanisms. Firstly, a direct effect of compounds on
the thyroid gland can lead to a decreased synthesis of thyroid
hormones, which has been reported in rats after exposure to the
commercial PCB mixture Aroclor 1254 (Collins and Capen,
1980). Secondly, the reduction in thyroid hormone levels can
be caused by enhanced biliary excretion of T4 due to the
induction of UDP-glucuronosyltransferases (UDP-GT; Barter
and Klaassen, 1992; Bastomsky, 1974; Van Birgelen et al.,
1995). The third known mechanism involved in reduced
plasma T4 levels is the observed binding of PCB metabolites to
the plasma thyroid hormone transport protein, transthyretin
(TTR), thereby displacing the natural ligand T4 (Brouwer and
van den Berg, 1986; Darnerud et al., 1996; Morse et al., 1996a;
Rickenbacher et al., 1986).
TTR is the only thyroid hormone binding plasma protein that
is synthesized both in liver and brain. It is suggested to serve
a role in mediating the delivery of T4 across the blood-brain
barrier and the maternal to fetal transport through the placenta
(Schreiber et al., 1995; Southwell et al., 1993). In addition,
TTR plays an essential role in the determination of free T4
levels in the extracellular compartment of the brain, which is
independent of the homeostasis of T4 in the body (Schreiber et
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361al., 1995). T4 in the brain is then converted to the active thyroid
hormone, triiodothyronine (T3) by speciﬁc deiodinases (type II
deiodinase). An increasing number of chemicals have been
reported to bind to human TTR in vitro. Parent PCB congeners
(Chauhan et al., 2000; Cheek et al., 1999; Rickenbacher et al.,
1986) but especially hydroxylated metabolites of PCBs,
dibenzo-p-dioxins and dibenzo-p-furans (Lans et al., 1993)
showed competitive binding to human TTR. Recently we were
able to detect a new class of compounds, the brominated ﬂame
retardants (e.g., polybrominated diphenyl ethers, brominated
bisphenols), with high in vitro T4-TTR competition binding
potency (Meerts et al., 2000).
The in vivo effects of the high binding afﬁnity of xenobiotics
such as hydroxylated polychlorinated biphenyls (OH-PCBs) to
TTR is hypothesized to result in (1) a selective retention of
these compounds in plasma, (2) facilitated transport of the
metabolites over the placenta to the fetal compartment, and (3)
decreased maternal and fetal plasma T4 levels by competition
with the natural ligand T4 (reviewed by Brouwer et al., 1998).
Several studies support this hypothesis. Bergman et al. (1994)
detected several OH-PCBs, with high in vitro T4-TTR binding
potency, in human serum and wildlife samples environmen-
tally exposed to PCBs. Exposure of rats to 3,3,4,4-tetrachlo-
robiphenyl resulted in selective retention of hydroxylated me-
tabolites in plasma and caused marked reductions in plasma
thyroxine levels (Brouwer et al., 1990) and vitamin A transport
(Brouwer and Van den Berg, 1986) via their binding to TTR.
In addition, maternal exposure of rats to Aroclor 1254 from
gestation days 10 to 16 resulted in selective accumulation of
the metabolite 4-OH-2,3,3,4,5-pentachlorobiphenyl (4-OH-
CB107) in fetal plasma and brain (Morse et al., 1996a) and was
accompanied by very low concentrations of T4 in both tissues.
In a comparable study conducted in mice, Darnerud et al.
(1996) showed a high and selective accumulation of 4-OH-
3,3,4,5-tetrachlorobiphenyl in fetal mouse plasma and reduc-
tions in thyroid hormone levels after maternal exposure to
3,3,4,4-tetrachlorobiphenyl. They were able to identify the
metabolite in fetal plasma bound to TTR.
In vivo toxicity data on the effects of hydroxylated PCB-
congeners on thyroid hormone homeostasis are scarce, since
most in vivo studies are conducted with parent compounds that
can exert effects of their own (e.g., induction of UDP-GT) and
undergo metabolism in the exposed animal to different metab-
olites. Therefore, in the present study we investigated the
effects of maternal exposure to the synthesized PCB metabolite
4-OH-CB107 on maternal and fetal rat thyroid hormone ho-
meostasis. To determine maternal to fetal transfer, we also
studied the uptake and distribution of
14C radiolabeled 4-OH-
CB107. We chose this metabolite, because it was one of the
major metabolites identiﬁed in human blood samples (Berg-
man et al., 1994), and was shown to accumulate in fetal plasma
and brain after maternal exposure to Aroclor 1254 (Morse et
al., 1996a). Furthermore, 4-OH-CB107 was shown to be a
metabolite, formed via a 1,2-shift of a chlorine atom, of
2,3,3,4,4-pentachlorobiphenyl (CB-105) and of 2,3,4,4,5-
pentachlorobiphenyl (CB-118; Sjo ¨din et al., 1998). Both PCB
congeners are present in adipose tissue of humans and wildlife
and can thus slowly be biotransformed to the 4-OH-CB107 that
is retained in the blood. We especially focused on testing the
hypothesis that binding of a PCB metabolite to transthyretin in
vivo would lead to facilitated transfer of the compound to the
fetal compartment resulting in decreased thyroid hormone lev-
els in fetal plasma and brain.
MATERIALS AND METHODS
Chemicals. 4-Hydroxy-2,3,3,4,5-pentachloro-[
14C]biphenyl (speciﬁc ac-
tivity: 15.6 mCi/mmol) was prepared from 3,4-dichloroiodo-[
14C]benzene,
prepared from 3,4-dichloro-[
14C]aniline after this compound had been meth-
ylated with diazomethane and reacted with iodine, and 2,3,6-trichloro-4-
iodoanisol via an Ullman reaction (Bergman et al., 1990). 4-Hydroxy-
2,3,3,4,5-pentachloro-[
14C]biphenyl was isolated in a chemical and
radiochemical purity  98%. Unlabeled 4-hydroxy-2,3,3,4,5-pentachlorobi-
phenyl (4-OH-CB107,  99%) was synthesized as described by Bergman et al.
(1995). Isopropanol, bovine serum albumin, sucrose, Tris, hydrogen peroxide
(H2O2), potassium hydroxide, Triton X-100, diisopropyl ether, dithiothreitol,
and methanol (all solvents were analytical grade) were purchased from Merck
Chemical Company (Darmstadt, Germany). Human prealbumin (TTR, 98%
pure) was obtained from Sigma Chemical Company (St. Louis, MO). [
125I]-
L-3,5-Thyroxine (spec. act. 46 Ci/g) was from Orange Medical (Tilburg,
The Netherlands).
Animals. All experimental procedures involving animals were approved
by the Animal Welfare Committee of the Wageningen University. Wistar WU
rats (60 females, 30 males; 14 weeks old) were purchased from Charles River
(Sulzfeld, Germany) and allowed to acclimatize for 3 weeks. Throughout the
experiment, animals were kept in an artiﬁcial 12:12-h light-dark cycle with
lights on at 0600 h. Room temperature was maintained at 21  2°C and
humidity at 50  10%. Animals were provided rat chow (Hope Farms,
Woerden, The Netherlands) and tap water ad libitum.
After the acclimatization period 2 females were placed in a cage with 1 male
overnight from 1700 to 800 h. Copulation was determined each morning by
checking the presence of sperm in the vaginal smear. When spermatozoa were
found, this day was designated as day 0 of gestation (GD 0) and females were
housed individually. Body weight of the dams was measured throughout
gestation. On day 10 of gestation the pregnant rats were divided randomly into
the different treatment groups and transferred to a macrolon, stainless steel
cage to facilitate the collection of feces.
Study on uptake and distribution of [
14C]-labeled 4-OH-CB107 in dams
and fetuses. For investigating the uptake and distribution, 6 pregnant rats
received a daily po dose of 2.3 Ci [
14C]-labeled 4-OH-CB107 per kg body
weight diluted with unlabeled 4-OH-CB107 for a total exposure dose of 14.6
mol (5 mg) 4-OH-CB107 per kg body weight per day from GD 10 to 16. The
metabolite was dissolved in corn oil, 5 mg/2 ml. Feces and urine were collected
daily. On GD 17 and GD 20, 3 dams per time point were sacriﬁced under ether
anesthesia and maternal blood was collected via the vena cava in heparinized
tubes. Maternal kidneys, liver, adrenals, pancreas, lungs, thymus, forebrain,
cerebellum, brown adipose tissue, skeletal muscle, and abdominal fat were
collected for radioactivity analyses. Individual placental/fetal units were care-
fully removed from the uterus. Fetuses were separated from the placenta,
blotted dry with tissue paper, and weighed. Fetal trunk blood, obtained by
decapitation, was collected in heparinized tubes, pooled per litter, and stored
on ice until plasma was prepared for thyroid hormone analysis and radioac-
tivity determinations. From 17-day-old fetuses, livers and brains (separated
into forebrain and cerebellum) were collected and pooled per litter. From
20-day-old fetuses, lungs and kidneys were additionally collected and pooled
per litter. Organs and placentas were rinsed with 0.9% sodium chloride, blotted
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–20°C. Cages were rinsed with 200 ml Triton X-100 at the end of the
experiment to determine losses of radioactivity. Maternal and fetal plasma,
liver, and brain samples were also used in biochemical assays described below
(n  3 per time point).
Study on biochemical effects of 4-OH-CB107 in dams and fetuses. In a
parallel experiment, pregnant rats received a daily po dose of 0 or 5 mg
4-OH-CB107 per kg body weight dissolved in corn oil (2 ml/kg body weight)
from GD 10 to GD 16. On GD 17 and GD 20, 4 dams per time point and
exposure were sacriﬁced under ether anesthesia and maternal blood was
collected via the vena cava in heparinized tubes. Fetuses were removed and
weighed. Fetal trunk blood was collected in heparinized tubes and pooled per
litter. Fetal liver and thymus were collected, weighed, frozen on dry ice, and
pooled per litter. Fetal brains were removed, separated into forebrain and
cerebellum, and frozen on dry ice. One fetal forebrain per litter was saved
separately for thyroid hormone analysis, the remaining forebrains and cerebella
were pooled per litter for analysis of thyroid hormone metabolism and stored
at –80°C. From the dams, liver, brain, thymus, and plasma were isolated,
frozen in liquid nitrogen and stored at –80°C until analysis.
Tissue radioactivity concentrations. Approximately 60 to 100 mg of
tissues or tissue homogenates and 25–50 l of the plasma samples were
dissolved in 1 ml Soluene-350 (Packard, St. Louis, MO) in glass scintillation
vials. Samples were bleached with 0.5 ml 30% H2O2, and total radioactivity
was measured 2 days later with 20 ml Hionic Fluor scintillation ﬂuid (Packard)
in a Packard 1600 liquid scintillation counter (LSC). Fecal samples were
homogenized with a mortar under liquid nitrogen. Aliquots ( 50 mg) of feces
homogenates were exactly weighed and solubilized with 1 ml Soluene-350 at
50°C during 1–2 h in closed glass scintillation vials. After addition of 0.5 ml
isopropanol samples were incubated at 50°C for another 2 h. Samples were
bleached by the addition of 0.6 ml 30% H2O2, and total radioactivity was
measured 2 days later with 20 ml Hionic Fluor by LSC. The carcasses of dams
and fetuses were dissolved in 700 ml (dams) or 200 ml (fetuses) 1.5 M
potassium hydroxide containing 20% ethanol (v/v). After homogenization
using an Ultra Turrax 0.5 ml aliquots (in total n  10) were bleached with 0.6
ml 30% H2O2 and total radioactivity was measured 2 days later with 20 ml
Hionic Fluor. The efﬁciency of counting was determined by quenching cor-
rection curves for the various additions and scintillation ﬂuids. In order to
estimate total radioactivity concentrations in plasma and skeletal muscle, the
total weight of plasma and skeletal muscle was set at 4 and 40% of the total
body weight, respectively.
Sample processing for biochemical purposes. Livers were thawed on ice
and homogenized in ice-cold 0.1 M Tris–HCl buffer, pH 7.5, containing 0.25
M sucrose (3 ml/g liver) using a Potter tube. The homogenate was centrifuged
for 30 min at 9000  g (4°C). The resulting supernatant was centrifuged for
90 min at 105,000  g (4°C). The microsomal pellet was resuspended in 0.1
M phosphate buffer (pH 7.5). Microsomes were stored in aliquots of 1 ml at
–80°C until further analysis.
Maternal and fetal (pooled per litter) forebrains were homogenized in a
Potter tube in 8 volumes ice-cold 0.1 M Tris-HCl buffer (pH 7.5) containing
1 mM dithiothreitol and stored at –80°C until further analysis. Protein levels
in different tissue fractions were determined using the BioRad Protein reagent
(Bradford, 1976).
Thyroid hormone analysis. Plasma total T4 (TT4), free T4 (FT4), and total
T3 (TT3) were analyzed in duplicate using chemiluminescence kits. Plasma
thyroid stimulating hormone (TSH) concentrations were analyzed with a
speciﬁc rat TSH immunoassay. All kits were purchased from Amersham
(Amersham, Buckinghamshire, UK).
Brain T4 and T3 concentrations were determined by speciﬁc RIAs in puriﬁed
extracts, as described before (Morreale de Escobar et al., 1985). Brieﬂy,
maternal and fetal forebrain and cerebellum samples were homogenized in
methanol, extracted in chloroform-methanol and back-extracted into an aque-
ous phase. This aqueous phase was puriﬁed through Bio-Rad AG 12 resin
columns (Bio-Rad Laboratories, Richmond, VA), and the iodothyronines were
eluted with 70% acetic acid, which was evaporated to dryness. The iodothy-
ronines were analyzed in highly sensitive RIAs in duplicate at 2 different
dilutions. Recovery of the extraction procedure was determined in each ho-
mogenate by the addition of tracer amounts of [
131I]-T4 and [
125I]-T3.
Thyroid hormone metabolism. Hepatic microsomal T4 uridine diphospho-
glucuronosyl transferase activity (UDP-GT) was determined as described by
Beetstra et al. (1991) and Visser et al. (1993). In short, microsomes (1 mg
protein per ml) were incubated for 30 min at 37°C with 1 MT 4 and 50,000
cpm [
125I]-T4, 5 mM uridine 5-diphosphoglucuronic acid, 3.75 mM MgCl2 and
0.125% (w/v) BSA in 75 mM Tris–HCl buffer (pH 7.8). The ﬁnal reaction
volume was 0.2 ml. The reaction was stopped by addition of 0.2 ml ice-cold
methanol, and after centrifugation 0.2 ml supernatant was mixed with 0.8 ml
0.1 N HCl. The amount of [
125I]-T4 glucuronide was analyzed by Sephadex
LH-20 chromatography (Rutgers et al., 1989).
Hepatic type I 5-deiodinase activity (D-I) was measured in duplicate in
microsomes as described by Mol and Visser (1985). Brieﬂy, microsomes (25
g protein/ml) were incubated for 30 min at 37°C with 1 Mr T 3 and 100,000
cpm [
125I-rT3] in 0.1 M phosphate buffer (pH 7.4) containing 2 mM EDTA and
5 mM DTT. The ﬁnal reaction volume was 0.2 ml. The reaction was stopped
by addition of 0.75 ml 0.1 M HCl, and the resulting [
125I] was separated from
the reaction mixture by Sephadex LH-20 chromatography according to Rutgers
et al. (1989). Blanks contained microsomes, inactivated by heating.
Brain type II thyroxine 5-deiodinase activity (D-II) was analyzed as de-
scribed by Visser et al. (1982) with slight modiﬁcations. Brieﬂy, brain ho-
mogenates (0.8 mg protein/ml) were incubated with 2 nM T4 and  50,000
cpm [
125I]-T4, 500 nM T3 and 1 mM propyl-2-thiouracil in 0.1 M phosphate
buffer pH 7.2 containing 1 mM EDTA and 25 mM DTT in a total volume of
0.2 ml. Incubations were carried out at 37°C for 60 min. The reaction was
stopped on ice by the addition of 0.1 ml 7% (w/v) BSA, followed by 0.5 ml
10% (w/v) trichloroacetic acid. The tubes were centrifuged at 4000 rpm in an
eppendorf centrifuge for 5 min and the amount of radioiodide released was
determined in 0.5 ml of the supernatant using Sephadex LH-20 chromatogra-
phy as described above. Blanks contained brain homogenates, which were
inactivated by boiling for 10 min.
Ethoxy- and pentoxyresoruﬁn-O-deethylase activity. Ethoxyresoruﬁn-O-
deethylase (EROD) activity was measured according to the method of Burke
et al. (1977) adapted for the use in 96-well plates and a ﬂuorospectrophoto-
metric plate reader (Cytoﬂuor 2350, Millipore, Etten-Leur, the Netherlands).
The reaction was performed with 0.1 mg liver microsomal protein per ml in 0.1
M Tris–HCl (pH 7.8) containing 0.4 M ethoxyresoruﬁn (ER), 1 mg/ml BSA,
and 0.1 mM NADPH in a total volume of 0.2 ml. The reaction mixtures were
preincubated at 37°C for 2 min, and the reaction was started by the addition of
NADPH. Reactions were stopped after 10 min by adding 50 l 1 M NaOH.
The formation of resoruﬁn was detected ﬂuorimetrically (excitation 530 nm,
emission 590 nm) and compared with a calibration curve (0–150 nM resoru-
ﬁn). Incubations were carried out in duplicate and results were corrected for
blank microsomal incubations without NADPH.
Pentoxyresoruﬁn-O-deethylase (PROD) activity was measured following
the same procedure as described above for EROD, with ﬁnal concentrations of
2 M pentoxyresoruﬁn (PR) and 0.1 mg microsomal protein/ml.
Plasma protein separation and [
125I]-T4 competition binding. To deter-
mine the binding of the PCB metabolite to plasma proteins in vivo, plasma samples
from [
14C]-4-OH-CB107 treated animals (dams and fetuses) were separated by
polyacrylamide gelelectrophoresis (PAGE) as described by Brouwer and Van den
Berg (1986). In addition, the determination of [
125I]-T4-competitive binding to
speciﬁc plasma proteins was performed as described by Lans et al. (1993) and
Darnerud et al. (1996). In short, plasma samples for gel slices (40 l) were mixed
1:1 with a 50 mM Tris/38 mM glycine buffer (pH 8.3) containing 4.5% saccha-
rose. Plasma samples for [
125I]-T4 competition binding (25 l) were incubated
overnight with 100,000 cpm [
125I]-T4 (in 5 l 50 mM Tris–HCl buffer, pH 8.0) at
4°C. Aliquots of 20 l of the different samples were run on a 10% native
separating gel for4ha t4 °C at a constant current of 50 mA. Each gel also
contained plasma samples for protein staining (5 l) and pure BSA and human
TTR as a reference. After electrophoresis, the part of the gel containing the
reference proteins was stained in 0.04% Coomassie Brilliant Blue in 3.5% per-
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to determine the position of the proteins on the gel. The part of the gel for
radioactivity measurements was frozen on the glass plate at –20°C overnight. The
acrylamide gel was subsequently sliced into 1 mm pieces by a standardized
procedure. Proteins in slices containing [
14C]-4-OH-CB107-derived radioactivity
were ﬁrst eluted by incubating the gel slices in tubes with 1 ml water overnight at
4°C. Four ml of scintillation ﬂuid was added (Ultima Gold, Packard) the next day
and the amount of radioactivity in each gel slice was quantiﬁed by LSC. Gel slices
containing plasma samples incubated with [
125I]-T4 were placed in RIA tubes and
counted directly in a -counter (Cobra Auto Gamma Counter, Canberra Packard).
The PAGE gel proﬁle was made by plotting the [
125I]-T4-radioactivity against the
migration distance on the gel.
In vitro T4-TTR competition binding study with 4-OH-CB107. The in
vitro potency of 4-OH-CB107 to compete with T4 for binding to human
transthyretin was performed as described by Lans et al. (1993) with modiﬁ-
cations (Meerts et al., 2000). Brieﬂy, 30 nM human TTR, a mixture of
[
125I]-labeled and unlabeled T4 (70,000 cpm, 55 nM), and 4-OH-CB107 (in
concentrations ranging from 10
–9 to 10
–4 M) were dissolved in 0.1 M Tris–
HCl-buffer (pH 8.0, containing 0.1 M NaCl and 0.1 mM EDTA). The incu-
bation mixture was allowed to reach binding equilibrium overnight at 4°C.
Protein-bound and free [
125I]-T4 were separated on 1 ml Biogel P-6DG col-
umns and spin-forced eluted with 0.2 ml Tris–HCl buffer (1 min at 100  g
in a precooled centrifuge, Difuge, Hereaus). Radioactivity in the eluate con-
taining the protein-bound [
125I]-T4 was determined by gamma counting and
compared to control incubations. The competition binding curves for T4 and
4-OH-CB107 were made by plotting relative [
125I]-T4-protein binding (% of
control) against concentration competitor.
Statistical analysis. Data are presented as mean values ( SEM). Com-
parisons between 2 groups of animals were performed using Student’s t test.
RESULTS
Fecal and Urinary [
14C]-4-OH-CB107 Excretion
Fecal elimination of [
14C]-4-OH-CB107-derived radioactiv-
ity was high. After 1 day exposure (GD 11), 15.1  1.8% of
the administered dose could be detected in the feces (Fig. 1),
but at GD 13 this level was raised to 60.6  6.5% of the total
dose administered. At GD 17 and GD 20, 78.4  6.1% and
93.8  6.9% of the total dose was excreted in the feces,
respectively. Urinary excretion was lower than 1% of the total
given dose (data not shown). The average recovery of radio-
activity per rat for animals dissected at GD 17 or GD 20 was
91.2  6.3% and 97.2  5.3%, respectively.
FIG. 1. Cumulative fecal excretion of [
14C]-derived radioactivity from
pregnant rats after po exposure to 5 mg [
14C]-4-OH-CB107 per kg per day from
GD 10–16. Data are expressed in dpm (result of 1 representative animal).
TABLE 1
Distribution of [
14C]-4-OH-CB 107-Derived Radioactivity in Maternal Tissues at Day 17 and Day 20 of Gestation
Tissue/organ
Distribution by weight Distribution by organ
GD 17 GD 20 GD 17 GD 20
Plasma 39.02  3.51 32.3  5.09 415.5  7.27 374.7  6.90
Liver 4.85  0.48 3.17  0.07 49.08  4.31 32.84  1.44
Kidney 4.51  0.4 2.86  0.02* 7.70  0.12 4.10  0.17
Lung 4.27  1.20 3.07  0.62 4.96  1.32 3.32  0.87
Thyroid 3.79  0.19 1.54  0.18** 0.074  0.02 0.04  0.01
Thymus 3.22  0.66 3.16  0.89 1.05  0.15 0.92  0.29
Adrenals 3.12  0.34 2.52  0.06 0.23  0.02 0.15  0.003*
Pancreas 2.95  0.35 2.16  0.10 1.49  0.20 0.73  0.09
Forebrain 1.47  0.08 0.96  0.12* 1.84  0.07 1.20  0.14*
Cerebellum 1.52  0.09 1.16  0.34 0.68  0.01 0.55  0.18
Skeletal muscle 1.17  0.25 0.28  0.09 97.4  12.1 30.8  8.5
Abdominal fat 1.96  0.04 1.18  0.63 ——
Brown adipose tissue 2.96  0.19 2.19  0.58 ——
Note. After oral exposure to 5 mg/kg body weight from GD 10–16. Data are expressed as nmol/g tissue (ﬁrst columns) or nmol/total organ (last columns),
and presented as mean  SE; n  3 per time point.
*Signiﬁcantly different from GD 17, p  0.05.
**Signiﬁcantly different from GD 17, p  0.01.
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In the pregnant rat, high levels of [
14C]-4-OH-CB107-de-
rived radioactivity could be detected in plasma, liver, and
skeletal muscle on whole organ basis (Table 1). Organ levels in
pregnant rats were higher at GD 17, i.e., 1 day after the last
treatment, compared to GD 20. Signiﬁcant decreases in radio-
activity concentrations at GD 20 could be detected in kidneys,
thyroid, and forebrain when levels were expressed in nmol per
gram fresh weight, and in adrenals and forebrain when ex-
pressed in nmol per total organ.
The distribution in the fetal compartment was different from
that in dams (Table 2). There is a substantial accumulation of
[
14C]-4-OH-CB107-derived radioactivity in the fetal compart-
ment. The total radioactivity concentrations in the fetal com-
partment were 51.7  3.2% of the total maternal concentra-
tions. Signiﬁcantly higher amounts of radioactivity could be
detected in fetal liver, forebrain, and cerebellum, whereas fetal
plasma levels were comparable to maternal levels (Table 2).
Fetal/maternal liver ratios were as high as 15.9  0.6 at GD 17
and 11.0  1.2 at GD 20 (Table 3). In addition, although levels
in maternal organs tend to decrease from GD 17 to 20, amounts
of [
14C]-4-OH-CB107 in fetal liver and cerebellum increased
when corrected for total tissue weight, though not signiﬁcantly.
Body and Organ Weights
No effects were observed on maternal body weight gain,
mean and total fetal body weight, number of implantation sites,
resorptions, number of fetuses, or sex ratio (data not shown). In
addition, absolute and relative organ weights from dams (liver,
brain, kidneys, adrenals, thyroid, thymus, spleen, pancreas) and
fetuses (liver, brain, kidneys, lungs) were not affected by
maternal exposure to 5 mg 4-OH-CB107 per kg body weight
from GD 10 to 16.
Plasma Thyroid Hormone Levels
Thyroid hormone analysis revealed a signiﬁcant decrease in
maternal total thyroxine (TT4) levels of 49% on GD 17 and
38% on GD 20 (Fig. 2A) following exposure to 5 mg 4-OH-
CB107 per kg body weight from GD 10 to GD 16. Maternal
free thyroxine (FT4, Fig. 2B) and total triiodothyronine (TT3,
Fig. 2C) levels were not signiﬁcantly reduced. At GD 20, fetal
total thyroxine (TT4) levels were drastically decreased by 89%
and FT4-levels were also signiﬁcantly reduced by 41% after in
utero exposure to the PCB metabolite (Figs. 3A and 3B). Fetal
TT4 levels on GD 17 could only be detected in the control
group (0.3  0.1 nM). The level in 4-OH-CB107-exposed
fetuses was below 0.09 nM, suggesting a decrease of at least
70% compared to the control group. Due to the small sample
size these measurements could not be repeated. Fetal plasma
levels of TSH were signiﬁcantly increased by 124% after
TABLE 2
Distribution of [
14C]-4-OH-CB107-derived Radioactivity in Fetal Tissues at Day 17 and 20 of Gestation
Tissue/organ
Distribution by weight Distribution by organ
GD 17 GD 20 GD 17 GD 20
Plasma n.a. 37.2  5.14 — 66.6  13.8*
Liver 89.41  8.17* 35.12  8.91* 58.7  9.18 89.08  10.1
Kidney n.a. 5.28  0.88 — 1.76  0.05*
Lung n.a. 4.08  0.24 — 4.69  0.56
Forebrain 3.11  0.03*** 1.54  0.49 2.02  0.11 1.69  0.40
Cerebellum 2.87  0.03** 2.63  0.34 0.99  0.02*** 1.42  0.24*
Placenta 6.22  0.46 5.02  1.01 35.8  3.66 28.6  5.41
Note. After exposure of the dams to 5 mg/kg body weight from GD 10–16. Fetal samples were pooled by litter. Data are expressed as nmol per g tissue (ﬁrst
columns) or nmol per total organ (last columns), and presented as mean  SE; n  3 per time point; n.a., not analyzed.
*Signiﬁcantly different from maternal levels at the same time point, p  0.05.
**Signiﬁcantly different from maternal levels at the same time point, p  0.005.
***Signiﬁcantly different from maternal levels at the same time point, p  0.0005.
TABLE 3
Fetal/Maternal Ratios of [
14C]-4-OH-CB107-derived
Radioactivity at Day 17 and 20 of Gestation
Tissue/organ
Fetal/maternal ratios
GD 17 GD 20
Plasma — 1.16  0.03
Liver 15.89  0.63 11.02  1.20
Kidney — 1.84  0.10
Lung — 0.89  0.09
Forebrain 2.12  0.09 1.10  0.10
Cerebellum 1.89  0.14 2.58  0.24
Note. Dams were exposed to 5 mg/kg body weight from GD 10 to 16.
Fetal/maternal ratios were calculated with levels expressed as nmol/g (see
Table 2). Fetal samples were pooled per litter; n  3 per time point and
exposure group.
365 IN UTERO EXPOSURE TO A PCB METABOLITE4-OH-CB107 treatment (Fig. 4). Maternal TSH-levels were
unchanged.
Brain Thyroid Hormone Levels
At GD 17, fetal cerebellum T4 and T3 levels were not
signiﬁcantly changed (Table 4). Forebrain T4 levels at GD 20
were signiﬁcantly reduced by 35% in 4-OH-CB107 treated
animals. Cerebellum T4 levels at GD 20 were also reduced,
though not signiﬁcantly (p  0.051). No reductions in fetal T3
levels could be detected in forebrain or cerebellum at GD 20.
Thyroid Hormone Metabolism
Maternal and fetal hepatic microsomal type I deiodinase
activities and T4 uridine diphosphoglucuronosyl transferase
activity (UDP-GT) were not altered by exposure to 4-OH-
CB107 (data not shown).
The activity of brain type II 5-thyroxine deiodinase (D-II)
in forebrain homogenates from 17-day-old fetuses is very low
compared to 20-day-old fetuses and maternal levels at GD 17
and GD 20. A signiﬁcant increase of 67% compared to controls
was observed at GD17 after exposure to 4-OH-CB107 (Fig. 5).
However, in 20-day-old fetuses, brain D-II levels were unaf-
fected. D-II levels in maternal forebrain homogenates were
decreased following exposure to 4-OH-CB107, though not
signiﬁcantly.
Ethoxy- and Pentoxyresoruﬁn-O-deethylase Activity
No effects were detected on maternal and fetal hepatic
microsomal EROD and PROD activity (data not shown).
Plasma Protein Separation and [
125I]-T4 Competition
Binding
Plasma protein separation from animals treated with [
14C]-
labeled 4-OH-CB107 revealed the binding of [
14C]-label to
transthyretin in both maternal and fetal plasma (Fig. 6). The
identiﬁcation of the transthyretin peak was based on co-migra-
tion of the TTR reference. In vitro T4-competition binding with
maternal plasma and separation of the plasma proteins by gel
electrophoresis showed 3 peaks with [
125I]-T4 bound radioac-
tivity (Fig. 7). The second peak represented transthyretin, and
the last one represented free T4. The third peak could not be
identiﬁed. The binding of [
125I]-T4 with maternal plasma
FIG. 2. Plasma levels of (A) maternal total thyroxine (TT4); (B) free thyroxine (FT4), and (C) total triiodothyronine (TT3) after po exposure to 5 mg
4-OH-CB107/kg body weight from GD 10–16. Results are presented as mean  SEM (n  7). *Statistically signiﬁcant differences with controls in Student’s
t-test (p  0.05).
FIG. 3. Plasma levels of (A) fetal
total thyroxine (TT4) and (B) free thyrox-
ine (FT4) after po exposure to 5 mg
4-OH-CB107/kg body weight from GD
10–16. Results are presented as mean 
SEM (n  7). Statistically signiﬁcant
differences with controls in Student’s t-
test, *(p  0.05) and ***(p  0.0001).
366 MEERTS ET AL.showed a signiﬁcant decrease of 45% in the amount of [
125I]-T4
bound to TTR in 4-OH-CB107 treated dams compared to
controls (Fig. 7A). The unbound radioactivity can be detected
at the front of the gel. In fetal plasma, this shift in the position
of radioactivity is not very clear (Fig. 7B). The amount of
[
125I]-T4 bound to TTR in fetuses treated in utero with 4-OH-
CB107 was slightly though not signiﬁcantly decreased.
In Vitro T4-TTR Competition Binding Study with 4-OH-
CB107
The binding afﬁnity (Ka) and IC50 value of 4-OH-CB107 as
determined in the in vitro T4-TTR competition binding assay
were 1.19 ( 0.01)  10
8 M
–1 and 24.4  2.2 nM, respectively
(Fig. 8). The relative potency compared to the natural ligand T4
(IC50 of 80.7 nM) was 3.3  0.3.
DISCUSSION
The results of the present study show that maternal exposure
to the PCB metabolite 4-OH-2,3,3,4,5-pentaCB from GD
10–16 results in considerable transfer of this metabolite from
the mother to the fetus, thereby affecting both maternal and
especially fetal thyroid hormone levels. Detection of 4-OH-
CB107 bound to transthyretin in fetal and maternal plasma
suggests that binding of a compound to TTR in vivo can lead
to facilitated maternal to fetal transfer, decreased maternal and
fetal plasma T4 levels, and decreased fetal brain T4 levels.
Hepatic UDP-GT levels were not induced in dams or fetuses,
indicating that this mechanism did not play a role in the
observed decrease in plasma thyroid hormone levels as shown
for e.g., TCDD and parent PCB-compounds (Darnerud et al.,
1986; Van Birgelen et al., 1995).
The internal dose of [
14C]-4-OH-CB107 in pregnant dams
was low, since most of the radioactivity was excreted in the
feces. However, relatively high levels of [
14C]-4-OH-CB107-
derived radioactivity could be detected in the fetal compart-
ment (i.e., 52% of the total maternal concentrations), indicating
a high placental transfer of the compound. At GD 17 and 20,
fetal liver, forebrain, and cerebellum levels were all higher than
maternal levels, whereas fetal plasma levels were almost equal
to maternal plasma levels (fetal/maternal ratio of 1.16  0.03
at GD 20). The approximate 16- and 11-fold higher levels in
fetal livers at GD 17 and 20, respectively, compared to mater-
FIG. 4. Plasma levels of thyroid stimulating hormone (TSH) in dams and
fetuses following prenatal exposure of rats to 5 mg 4-OH-CB107 per kg body
weight from GD 10–16. Results are presented as mean  SEM (n  7 per
exposure and time point). *Statistically signiﬁcant differences with controls in
Student’s t-test (p  0.05).
TABLE 4
Fetal Brain Thyroid Hormone Levels
Exposure Corn oil 4-OH-CB107
GD 17
Forebrain T4 n.a. n.a.
Forebrain T3 n.a. n.a.
Cerebellum T4 0.53  0.08 (6) 0.49  0.06 (6)
Cerebellum T3 0.14  0.02 (6) 0.12  0.01 (6)
GD 20
Forebrain T4 1.79  0.09 (4) 1.16  0.07 (5)***
Forebrain T3 0.91  0.06 (4) 0.80  0.05 (6)
Cerebellum T4 1.38  0.13 (4) 1.10  0.04 (5)
Cerebellum T3 0.18  0.02 (4) 0.16  0.01 (6)
Note. Data are presented as mean  SEM. The number of animals is given
in parentheses; n.a., not analyzed. Thyroid hormone levels are presented as ng
T4 or T3 per g tissue.
***Signiﬁcantly different from corn oil, p  0.001.
FIG. 5. Type II thyroxine 5 deiodinase (D-II) activity in forebrain ho-
mogenates from dams and fetuses at GD 17 and 20, following prenatal
exposure to 0 or 5 mg 4-OH-CB107 per kg body weight from GD 10–16.
Results are presented as mean  SEM (n  7). *Statistically signiﬁcant
differences in Student’s t-test (p  0.05).
367 IN UTERO EXPOSURE TO A PCB METABOLITEnal livers are striking. This may be due to the fact that the liver
is one of the major sites of TTR synthesis in the body (Dickson
et al., 1985). In addition, the 3.3-fold higher afﬁnity of 4-OH-
CB107 for TTR in vitro compared to the natural ligand T4 (this
study) and the observed in vivo binding of [
14C]-4-OH-CB107-
derived radioactivity (this study) are in line with this explana-
tion.
Signiﬁcant reductions (approximately 90%) in fetal plasma
TT4 levels at GD 20 could be detected after maternal exposure
to 4-OH-CB107, with fetal plasma metabolite levels of 12.7
g/g on wet weight basis. As a comparison, rats exposed to 5
or 25 mg/kg Aroclor 1254 in the same experimental setup
resulted in a 52 or 74% decrease in fetal plasma TT4, respec-
tively, with fetal plasma 4-OH-CB107 concentrations of ap-
proximately 0.6 and 1.6 g/g (Morse et al., 1996a). The higher
decreases in fetal free T4 levels and maternal total and free T4
levels after Aroclor 1254 exposure can be explained by the
additional induction of hepatic UDP-GT by Aroclor 1254 and
consequently induced biliary excretion of T4 after glucuronida-
tion. Surprisingly, exposure of pregnant mice to one single iv
FIG. 6. Distribution of [
14C]-derived radioactivity in maternal (A) and pooled fetal (B) plasma at GD 20 after native polyacrylamide gelelectrophoresis.
Pregnant rats were exposed to 5 mg [
14C]-labeled 4-OH-CB107 per kg body weight from GD 10–16.
FIG. 7. Distribution of [
125I]-T4-derived radioactivity in maternal (A) and pooled fetal (B) plasma after in vitro incubation with [
125I]-T4 and native PAGE.
Pregnant rats were treated with corn oil (dotted lines) or 5 mg 4-OH-CB107 per kg body weight from GD 10–16.
368 MEERTS ET AL.dose of 50 mol ( 17.1 mg) per kg body weight of another
PCB metabolite, 4-OH-2,3,3,4,5-pentaCB (5.9-fold higher
afﬁnity for TTR in vitro compared to T4, Lans et al., 1993)
resulted in an only 14% reduction of fetal plasma T4 levels
compared to control levels (Sinjari and Darnerud, 1998). How-
ever, comparison with this latter study is difﬁcult, since the
route of exposure, species, and time point of analysis were all
different.
Fetal plasma thyroid stimulating hormone levels were sig-
niﬁcantly increased at GD 20, indicating that the hypothala-
mus-pituitary-thyroid (HPT) axis was stimulated in the fetuses.
This was expected, since reductions in plasma T4 levels are
responsible for regulating fetal plasma TSH levels (Morreale
de Escobar et al., 1993). However, stimulation of this HPT axis
occurs at a stage when the setpoint of homeostatic control is
being developed, and it is possible that these disturbances
might have a prolonged effect on the homeostatic control of
thyroid hormones in these animals. Morse et al. (1996a) re-
ported normal levels of plasma thyroid hormones in offspring
exposed prenatally to 5 mg/kg Aroclor 1254 at day 21 post-
partum, but a statistically signiﬁcant elevation of plasma TT4
levels in male offspring at 90 days postpartum.
Despite the very low T4 levels in fetal plasma, fetal brain T4
levels were reduced only in forebrain and cerebellum homog-
enates at GD 20, and not at GD 17. It should be stated however,
that brain T4 and T3 levels at GD 17 were very difﬁcult to
measure because of small sample sizes, and we only used
cerebellum samples at GD 17 for thyroid hormone analysis. No
changes were observed in brain T3 levels at GD 17 or GD 20.
The induction of brain type II 5-thyroxine deiodinase (D-II) is
a well known response of the rat brain to maintain brain T3
levels when circulating T4 concentrations are decreased
(Obrego ´n et al., 1984; Ruiz de On ˜a et al., 1988; Silva and
Matthews, 1984), and has been reported before in fetal and
neonatal rats after maternal exposure to 3,3,4,4,5,5-hexa-
chlorobiphenyl (Morse et al., 1993) and Aroclor 1254 (Morse
et al., 1996a). Maternal exposure to Aroclor 1254 caused a
signiﬁcant decrease in fetal forebrain T4 levels, but not in T3
levels.
The accumulation of the 4-OH-CB107 in fetal forebrain and
cerebellum may have an effect on the neurodevelopment of the
offspring. In a comparable study by Morse et al. (1996a),
exposure of pregnant rats to Aroclor 1254 from GD 10 to 16
resulted in long-term alterations in glial and neuronal cell
marker proteins in the offspring (Morse et al., 1996b), and
signiﬁcant increases in 5-hydroxytryptamine (5-HT) metabo-
lism (Morse et al., 1996c). These adverse effects were likely
caused by 4-OH-CB107, since this metabolite accumulated in
fetal brains after maternal exposure to Aroclor 1254. Concen-
trations of 4-OH-CB107 in fetal brains (determined by GC/MS
analysis) at GD 20 were approximately 0.16 ppm on fresh
weight basis (Morse et al., 1996a). In the current study, ma-
ternal exposure of rats to 5 mg/kg 4-OH-CB107 resulted in
concentrations of 0.90 ppm 4-OH-CB107 in fetal cerebellum
and 0.53 ppm in fetal forebrain. In total, the brain 4-OH-
CB107 levels in this study were approximately 9 times higher
compared to maternal exposure to 25 mg/kg Aroclor 1254. To
investigate the effects of maternal 4-OH-CB107 exposure on
the development and behavior of the offspring in more detail,
a passive avoidance test (at PND 130) and catalepsy test (at
PND 168–175) was performed on the offspring and neuro-
transmitter concentrations were measured at autopsy. This
study revealed that developmental exposure to Aroclor 1254
affects both the dopaminergic and serotonergic system,
whereas exposure to 4-OH-CB107 affects dopaminergic and
noradrenergic systems (Meerts et al., manuscript in prepara-
tion).
OH-PCBs can also exert several other effects on the endo-
crine system. OH-PCBs have been reported to interact with
thyroid hormone metabolizing enzymes, such as iodothyronine
5-deiodinase (Adams et al., 1990; Lans, 1995; Rickenbacher
et al., 1989) and iodothyronine sulfotransferase (Schuur et al.,
1998) in vitro. In addition, some OH-PCBs competitively bind
to the estrogen receptor and exhibit estrogenic activity in the
mouse uterus (Korach et al., 1988). Recently, Kester et al.
(2000) demonstrated that various environmentally relevant
OH-PCBs were extremely potent inhibitors of human estrogen
sulfotransferases.
In conclusion, exposure of pregnant rats to the PCB metab-
olite 4-OH-CB107 results in drastic reductions in fetal plasma
thyroid hormone concentrations, and to an accumulation of the
compound in fetal liver, brain, and plasma. It is suggested that
the observed binding of 4-OH-CB107 to TTR may play a role
in the retention of the metabolite in plasma, in the maternal to
fetal transport and in the distribution of 4-OH-CB107 in the
fetal compartment. The question remaining is whether this
FIG. 8. Displacement of T4 from TTR by 4-OH-CB107. Data points are
mean values  SD of 1 representative measurement in duplicate. If no error
bar is visible, it is smaller than the marker. Relative [
125I]-T4-TTR binding is
presented as % of control value.
369 IN UTERO EXPOSURE TO A PCB METABOLITEpossible mechanism is also operating in humans. Even though
in humans thyroxine binding globulin is the main thyroid
hormone transport protein in the blood, TTR still plays a role
in mediating the delivery of T4 across the blood-brain barrier,
transporting T4 into the cerebrospinal ﬂuid and transferring
maternal-to-fetal T4 over the placenta (Calvo et al., 1990;
Southwell et al., 1993). In fact, current determinations of
4-OH-CB107 levels in human maternal plasma and cord blood
show approximately 3-fold higher levels in cord blood (Berg-
man et al., 1999), suggesting that indeed transport of OH-PCBs
to the human fetus is possible. If this facilitated transport is
also operating for other organohalogen compounds, further
investigation is needed into the possible consequences of ex-
posure to these compounds on neuronal development of the
offspring.
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